单位：[1]Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China临床科室泌尿外科泌尿外科首都医科大学附属北京友谊医院[2]Beijing Key Laboratory of Cancer Invasion and Metastasis Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Capital Medical University, Beijing, 100069, China
Although the management of patients with renal cell carcinoma (RCC) has changed drastically in recent years, it is still faced with the evolving challenge. Elucidation of the mechanisms underlying RCC will help the development of therapies, as well as biomarkers for early diagnosis. In this study, ccRCC tissues from patients in different stages were subject to iTRAQ-based proteomics analysis. 130 common differentially expressed proteins (DEPs) in different stages were found and lipid metabolism pathway was obviously dysregulated in all stages. These 130 common DEPs were enriched in four highly connected subnetworks including metabolic pathway, the TCA cycle, oxidative phosphorylation and fatty acid metabolism. ECHS1, a key enzyme in fatty acid metabolism, was further investigated. ECHS1 expression was significantly downregulated in ccRCC tissues and ECHS1 level discriminated ccRCC tissues in general and in stage I from adjacent normal tissues well and with the area under the receiver operating characteristic curve (AUC) of more than 0.7. ECHS1 overexpression suppressed RCC cell proliferation and migration through inhibiting mTOR pathway activation. ECHS1 may be a novel target for ccRCC therapeutic interventions and diagnostic biomarker for ccRCC.
基金：
National Natural Science Foundation of the People's Republic of ChinaNational Natural Science Foundation of China (NSFC) [81974415, 81672521, 81372739]; Natural Science Foundation of BeijingBeijing Natural Science Foundation [7192021]
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2019]版：
大类|3 区医学
小类|3 区医学：研究与实验3 区药学
最新[2025]版：
大类|2 区医学
小类|2 区医学：研究与实验2 区药学
JCR分区：
出版当年[2018]版：
Q1PHARMACOLOGY & PHARMACYQ2MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版：
Q1MEDICINE, RESEARCH & EXPERIMENTALQ1PHARMACOLOGY & PHARMACY
第一作者单位：[1]Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China
共同第一作者：
通讯作者：
通讯机构：[2]Beijing Key Laboratory of Cancer Invasion and Metastasis Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Capital Medical University, Beijing, 100069, China[*1]Department of Biochemistry and Molecular Biology, Capital Medical University, No. 10 Xitoutiao, You An Men, Beijing, 100069, China
推荐引用方式(GB/T 7714)：
Wang Lei,Qi Yijun,Wang Xi,et al.ECHS1 suppresses renal cell carcinoma development through inhibiting mTOR signaling activation[J].BIOMEDICINE & PHARMACOTHERAPY.2020,123:doi:10.1016/j.biopha.2019.109750.
APA：
Wang, Lei,Qi, Yijun,Wang, Xi,Li, Lanxin,Ma, Yuanzhen&Zheng, Junfang.(2020).ECHS1 suppresses renal cell carcinoma development through inhibiting mTOR signaling activation.BIOMEDICINE & PHARMACOTHERAPY,123,
MLA：
Wang, Lei,et al."ECHS1 suppresses renal cell carcinoma development through inhibiting mTOR signaling activation".BIOMEDICINE & PHARMACOTHERAPY 123.(2020)
